Results 171 to 180 of about 883,171 (266)

Resolving Endoplasmic Reticulum‐Protein Misfolding Restores Corticosteroid Sensitivity in Experimental Models of Severe Asthma

open access: yesAllergy, Volume 81, Issue 9, Page 3221-3235, September 2026.
This study investigates the role of ER stress in steroid resistance in severe asthma. Results from advanced 3D models of human bronchial epithelial cells, steroid‐resistant severe asthma mouse models, and human severe asthma sputum samples show that treatment with ICS in combination with the ER stress inhibitor 4‐PBA significantly enhances steroid ...
Prabuddha S. Pathinayake   +8 more
wiley   +1 more source

When a Neisseria meningitidis PCR limitation contributes to an immunological disease diagnosis

open access: yesJournal of Microbiology, Immunology and Infection
Claire Duployez   +7 more
doaj   +1 more source

Longer Asthma Duration Is Associated With Elevated Non‐T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma

open access: yesAllergy, Volume 81, Issue 9, Page 3286-3299, September 2026.
Longer asthma duration is associated with increased airway non‐T2 inflammation and reduced airway and systemic T2 inflammation. Sputum CXCL9 is independently associated with duration and may predict a reduced poor response to anti‐IL‐4Rα therapy. Airway sampling and combined T2 and non‐T2 targeted strategies may be needed in long‐standing asthma. CXCL9,
Freda Yang   +298 more
wiley   +1 more source

The Airway Transcriptome in Type 2 Cytokine Biomarker‐High and ‐Low Severe Asthma

open access: yesAllergy, Volume 81, Issue 9, Page 3300-3317, September 2026.
This study distinguishes severe asthma–related airway transcriptomic changes from the effects of high‐dose ICS. Most dysregulated genes in severe asthma show concordance with corticosteroid responses. Corticosteroid‐resistant T2‐high asthma featured T2‐high and epithelial barrier gene upregulation, while T2‐low asthma featured Th1/IL‐17 signatures. ASM,
Jiashu Shen   +19 more
wiley   +1 more source

Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German–Austrian Expert Opinion Paper

open access: yesEuropean Journal of Neurology, Volume 33, Issue 9, September 2026.
ABSTRACT Background The therapeutic landscape of generalised myasthenia gravis (gMG) has evolved substantially with the approval of targeted immunotherapies, including complement C5 inhibitors (C5‐I) and neonatal Fc receptor inhibitors (FcRn‐I). While pivotal trials have demonstrated marked efficacy in defined subgroups, real‐world experience reveals ...
Andreas Meisel   +17 more
wiley   +1 more source

When to consider an inborn error of immunity: clues for physicians

open access: yesInternal Medicine Journal, Volume 56, Issue 9, Page 1488-1499, September 2026.
Abstract The term inborn errors of immunity (IEIs) refers to the rapidly expanding group of genetic disorders causing dysregulation of the immune system. With improved genetic testing in recent years, the number of defined IEIs and their range of phenotypic presentations has grown vastly, with more than 550 IEIs now described.
Meera Thangarajah, Lucinda J. Berglund
wiley   +1 more source

Home - About - Disclaimer - Privacy